Lixte Biotechnology Holdings, Inc. (8640.F)

Descripción

Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group and Oncode Institute, as well as Roche and the Netherlands Cancer Institute for conducting new clinical trial in immune therapy unresponsive metastatic colon cancer. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.